Z6尊龙官方网站

Guangdong Zhongsheng Raynovent Biotechnology Co., Ltd. held the national investigators conference of phase 2 clinical trial of ZSP1273 to treat Influenza A in Guangzhou, which marked the official initiation of phase 2 trial of ZSP1273, a new drug developed by Raynovent for the treatment and prevention of influenza A and human avian influenza.

Raynovent received the Certificate of Invention Patent (Hydroxyl purine compounds and applications) issued by the National Intellectual Property Administration, People's Republic of China.

Raynovent received the Certificate of Invention Patent (Hydroxyl purine compounds and applications) issued by Federal Service for Intellectual Property (Russia).

Today, the China Non-alcoholic Steatohepatitis (NASH) New Drug Alliance was official established in Shanghai. Dr. Chen Xiaoxin, Vice President of Raynovent was appointed as Vice President of Alliance.

Raynovent received the Certificate of Invention Patent (Hydroxyl purine compounds and applications) issued by United States Patent and Trademark Office.